258 related articles for article (PubMed ID: 22776233)
21. Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome.
Sanz-Ortega J; Vocke C; Stratton P; Linehan WM; Merino MJ
Am J Surg Pathol; 2013 Jan; 37(1):74-80. PubMed ID: 23211287
[TBL] [Abstract][Full Text] [Related]
22. Gene expression analysis in peripheral blood cells of patients with hereditary leiomyomatosis and renal cell cancer syndrome (HLRCC): identification of NRF2 pathway activation.
Arenas Valencia C; Lopez Kleine L; Pinzon Velasco AM; Cardona Barreto AY; Arteaga Diaz CE
Fam Cancer; 2018 Oct; 17(4):587-599. PubMed ID: 29302811
[TBL] [Abstract][Full Text] [Related]
23. Proteasome inhibition disrupts the metabolism of fumarate hydratase- deficient tumors by downregulating p62 and c-Myc.
Sourbier C; Ricketts CJ; Liao PJ; Matsumoto S; Wei D; Lang M; Railkar R; Yang Y; Wei MH; Agarwal P; Krishna M; Mitchell JB; Trepel JB; Neckers L; Linehan WM
Sci Rep; 2019 Dec; 9(1):18409. PubMed ID: 31804603
[TBL] [Abstract][Full Text] [Related]
24. The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels.
Tong WH; Sourbier C; Kovtunovych G; Jeong SY; Vira M; Ghosh M; Romero VV; Sougrat R; Vaulont S; Viollet B; Kim YS; Lee S; Trepel J; Srinivasan R; Bratslavsky G; Yang Y; Linehan WM; Rouault TA
Cancer Cell; 2011 Sep; 20(3):315-27. PubMed ID: 21907923
[TBL] [Abstract][Full Text] [Related]
25. Fumarase: a mitochondrial metabolic enzyme and a cytosolic/nuclear component of the DNA damage response.
Yogev O; Yogev O; Singer E; Shaulian E; Goldberg M; Fox TD; Pines O
PLoS Biol; 2010 Mar; 8(3):e1000328. PubMed ID: 20231875
[TBL] [Abstract][Full Text] [Related]
26. Review: Warburg effect and renal cancer caused by errs in fumarate hydratase encoding gene.
Qureshi AS; Ali S
Pak J Pharm Sci; 2019 Mar; 32(2):743-749. PubMed ID: 31081789
[TBL] [Abstract][Full Text] [Related]
27. CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma.
Ooi A; Dykema K; Ansari A; Petillo D; Snider J; Kahnoski R; Anema J; Craig D; Carpten J; Teh BT; Furge KA
Cancer Res; 2013 Apr; 73(7):2044-51. PubMed ID: 23365135
[TBL] [Abstract][Full Text] [Related]
28. Sustained NRF2 activation in hereditary leiomyomatosis and renal cell cancer (HLRCC) and in hereditary tyrosinemia type 1 (HT1).
Sandhu IS; Maksim NJ; Amouzougan EA; Gallion BW; Raviele AL; Ooi A
Biochem Soc Trans; 2015 Aug; 43(4):650-6. PubMed ID: 26551707
[TBL] [Abstract][Full Text] [Related]
29. A chemoproteomic portrait of the oncometabolite fumarate.
Kulkarni RA; Bak DW; Wei D; Bergholtz SE; Briney CA; Shrimp JH; Alpsoy A; Thorpe AL; Bavari AE; Crooks DR; Levy M; Florens L; Washburn MP; Frizzell N; Dykhuizen EC; Weerapana E; Linehan WM; Meier JL
Nat Chem Biol; 2019 Apr; 15(4):391-400. PubMed ID: 30718813
[TBL] [Abstract][Full Text] [Related]
30. Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach.
Wyvekens N; Valtcheva N; Mischo A; Helmchen B; Hermanns T; Choschzick M; Hötker AM; Rauch A; Mühleisen B; Akhoundova D; Weber A; Moch H; Rupp NJ
Genes Chromosomes Cancer; 2020 Nov; 59(11):611-619. PubMed ID: 32537760
[TBL] [Abstract][Full Text] [Related]
31. Association of germline mutations in the fumarate hydratase gene and uterine fibroids in women with hereditary leiomyomatosis and renal cell cancer.
Stewart L; Glenn GM; Stratton P; Goldstein AM; Merino MJ; Tucker MA; Linehan WM; Toro JR
Arch Dermatol; 2008 Dec; 144(12):1584-92. PubMed ID: 19075141
[TBL] [Abstract][Full Text] [Related]
32. Fumarate hydratase as a therapeutic target in renal cancer.
Kancherla P; Daneshvar M; Sager RA; Mollapour M; Bratslavsky G
Expert Opin Ther Targets; 2020 Sep; 24(9):923-936. PubMed ID: 32744123
[TBL] [Abstract][Full Text] [Related]
33. [FH-deficient renal cell carcinoma expands the spectrum of renal papillary tumors].
Rupp N; Moch H
Pathologe; 2021 Nov; 42(6):560-564. PubMed ID: 34448900
[TBL] [Abstract][Full Text] [Related]
34. Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma.
Kopp RP; Stratton KL; Glogowski E; Schrader KA; Rau-Murthy R; Russo P; Coleman JA; Offit K
Cancer; 2017 Jul; 123(13):2452-2458. PubMed ID: 28171700
[TBL] [Abstract][Full Text] [Related]
35. Fumarate Hydratase-deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome.
Trpkov K; Hes O; Agaimy A; Bonert M; Martinek P; Magi-Galluzzi C; Kristiansen G; Lüders C; Nesi G; Compérat E; Sibony M; Berney DM; Mehra R; Brimo F; Hartmann A; Husain A; Frizzell N; Hills K; Maclean F; Srinivasan B; Gill AJ
Am J Surg Pathol; 2016 Jul; 40(7):865-75. PubMed ID: 26900816
[TBL] [Abstract][Full Text] [Related]
36. Detailed Morphologic and Immunohistochemical Characterization of Myomectomy and Hysterectomy Specimens From Women With Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome (HLRCC).
Chan E; Rabban JT; Mak J; Zaloudek C; Garg K
Am J Surg Pathol; 2019 Sep; 43(9):1170-1179. PubMed ID: 31162287
[TBL] [Abstract][Full Text] [Related]
37. Hereditary Leiomyomatosis and Renal Cell Cancer: Clinical, Molecular, and Screening Features in a Cohort of 185 Affected Individuals.
Forde C; Lim DHK; Alwan Y; Burghel G; Butland L; Cleaver R; Dixit A; Evans DG; Hanson H; Lalloo F; Oliveira P; Vialard L; Wallis Y; Maher ER; Woodward ER
Eur Urol Oncol; 2020 Dec; 3(6):764-772. PubMed ID: 31831373
[TBL] [Abstract][Full Text] [Related]
38. A novel missense mutation in fumarate hydratase in an Italian patient with a diffuse variant of cutaneous leiomyomatosis (Reed's syndrome).
Rongioletti F; Fausti V; Ferrando B; Parodi A; Mandich P; Pasini B
Dermatology; 2010; 221(4):378-80. PubMed ID: 21051878
[TBL] [Abstract][Full Text] [Related]
39. Renal cell carcinoma in young FH mutation carriers: case series and review of the literature.
Hol JA; Jongmans MCJ; Littooij AS; de Krijger RR; Kuiper RP; van Harssel JJT; Mensenkamp A; Simons M; Tytgat GAM; van den Heuvel-Eibrink MM; van Grotel M
Fam Cancer; 2020 Jan; 19(1):55-63. PubMed ID: 31792767
[TBL] [Abstract][Full Text] [Related]
40. Fumarate hydratase deficient renal cell carcinoma and fumarate hydratase deficient-like renal cell carcinoma: Morphologic comparative study of 23 genetically tested cases.
Pivovarčíková K; Martínek P; Trpkov K; Alaghehbandan R; Magi-Galluzzi C; Mundo EC; Berney D; Suster S; Gill A; Rychlý B; Michalová K; Pitra T; Hora M; Michal M; Hes O
Cesk Patol; 2019; 55(4):244-249. PubMed ID: 31842557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
